$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2023 Q1 Form 10-K Financial Statement

#000143774923008502 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.501M $1.477M $5.359M
YoY Change -7.38% 13.41% 2.01%
% of Gross Profit
Research & Development $5.235M $6.297M $18.95M
YoY Change -10.21% 136.5% 290.55%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $6.736M $7.774M $24.31M
YoY Change -9.59% 96.08% 140.55%
Operating Profit -$6.736M -$24.31M
YoY Change -9.59% 140.55%
Interest Expense $7.655K $125.8K $182.8K
YoY Change -3428.26% 8124.84% -7685.06%
% of Operating Profit
Other Income/Expense, Net $136.0K -$461.7K -$11.91K
YoY Change 53.18% -266.0% -100.75%
Pretax Income -$6.600M -$8.110M -$24.32M
YoY Change -10.35% 120.08% 185.57%
Income Tax $2.978K $8.360K $20.78K
% Of Pretax Income
Net Earnings -$6.600M -$8.118M -$24.30M
YoY Change -10.39% 120.31% 185.15%
Net Earnings / Revenue
Basic Earnings Per Share -$0.30 -$1.25
Diluted Earnings Per Share -$0.30 -$0.37 -$1.25
COMMON SHARES
Basic Shares Outstanding 20.45M 20.44M 19.52M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.26M $18.52M $18.52M
YoY Change -51.94% -37.62% -37.62%
Cash & Equivalents $11.26M $18.52M
Short-Term Investments
Other Short-Term Assets $1.646M $403.8K $403.8K
YoY Change -10.89% -76.47% -76.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.90M $18.92M $18.92M
YoY Change -48.94% -39.74% -39.74%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.00 -$5.00 $0.00
YoY Change 50.0% -600.0%
TOTAL ASSETS
Total Short-Term Assets $12.90M $18.92M $18.92M
Total Long-Term Assets $3.00 -$5.00 $0.00
Total Assets $12.90M $18.92M $18.92M
YoY Change -48.94% -39.74% -39.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.861M $3.520M $3.520M
YoY Change 100.62% 590.81% 590.82%
Accrued Expenses $3.032M $2.520M $2.520M
YoY Change 37.97% 37.29% 37.29%
Deferred Revenue
YoY Change
Short-Term Debt $667.5K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.560M $6.040M $6.040M
YoY Change 81.05% 157.58% 157.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $556.3K $567.4K $567.4K
YoY Change 96.08% 52.24% 52.24%
Total Long-Term Liabilities $556.3K $567.4K $567.4K
YoY Change 96.08% 52.24% 52.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.560M $6.040M $6.040M
Total Long-Term Liabilities $556.3K $567.4K $567.4K
Total Liabilities $7.117M $6.607M $6.607M
YoY Change 82.14% 143.13% 143.13%
SHAREHOLDERS EQUITY
Retained Earnings -$97.80M -$91.20M
YoY Change 31.81% 36.46%
Common Stock $2.045K $2.045K
YoY Change 35.16% 41.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.785M $12.32M $12.32M
YoY Change
Total Liabilities & Shareholders Equity $12.90M $18.92M $18.92M
YoY Change -48.94% -39.74% -39.74%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$6.600M -$8.118M -$24.30M
YoY Change -10.39% 120.31% 185.15%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$7.951M -$4.691M -$18.96M
YoY Change 26.88% 20.21% 77.73%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $687.1K 18.56K $7.792M
YoY Change 981461.43% -81.15% -75.34%
NET CHANGE
Cash From Operating Activities -$7.951M -4.691M -$18.96M
Cash From Investing Activities
Cash From Financing Activities $687.1K 18.56K $7.792M
Net Change In Cash -$7.264M -4.672M -$11.17M
YoY Change 15.92% 22.83% -153.37%
FREE CASH FLOW
Cash From Operating Activities -$7.951M -$4.691M -$18.96M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1591055 usd
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
100000 usd
CY2022Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 usd
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
11200000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20452121
CY2022 dei Auditor Firm
AuditorFirmId
32
CY2022 dei Auditor Name
AuditorName
ArmaninoLLP
CY2022 dei Auditor Location
AuditorLocation
San Ramon, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18519856 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29687944 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
403819 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1716057 usd
CY2022Q4 us-gaap Assets
Assets
18923675 usd
CY2021Q4 us-gaap Assets
Assets
31404001 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6039840 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
567439 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6607279 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20447371
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14433286
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14433286
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2045 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1443 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103485612 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95516986 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91171261 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66831969 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12316396 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18923675 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31404001 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18947874 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4851602 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-24306608 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-10104513 usd
CY2022 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-194709 usd
CY2022 rvph Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
182802 usd
CY2021 rvph Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-2414 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11907 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24318515 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20777 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24339292 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19516479
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5465750 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31497463 usd
CY2021 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
98481 usd
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
39929 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
106713 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8521876 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 usd
CY2022 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
18966 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7773527 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
176735 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24339292 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12316396 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8521876 usd
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
39929 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
176735 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
106713 usd
CY2022 rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
7773527 usd
CY2021 rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
31497463 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18966 usd
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
98481 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7792493 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31595944 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11168088 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
20927482 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29687944 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8760462 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
16484 usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
2400 usd
CY2022Q4 rvph Working Capital
WorkingCapital
12900000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91200000 usd
CY2022Q4 us-gaap Cash
Cash
18500000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24300000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8500000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<span style="text-decoration: underline; ">Use of estimates</span>The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, depreciative and amortization useful lives, assumptions used to calculate the fair value of stock-based compensation, warrant values, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span>Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash and cash equivalents are held in demand deposit form at two financial institutions. The Company has not experienced any losses on its deposits of cash.The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8500000 usd
CY2022Q3 rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
7800000 usd
CY2022Q3 rvph Issuance Of Equity Transaction Costs
IssuanceOfEquityTransactionCosts
700000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-24363000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8544000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
44000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
28000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24319000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8516000 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
9000 usd
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000 usd
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
12000 usd
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
6000 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
21000 usd
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
8000 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2022 rvph Income Tax Expense Benefit Including Immaterial Differences
IncomeTaxExpenseBenefitIncludingImmaterialDifferences
21000 usd
CY2021 rvph Income Tax Expense Benefit Including Immaterial Differences
IncomeTaxExpenseBenefitIncludingImmaterialDifferences
8000 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5103894 usd
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1788135 usd
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
4424 usd
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-58152 usd
CY2022 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
48653 usd
CY2021 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
-334122 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
10766 usd
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
8924 usd
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
2212 usd
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1414 usd
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
100365 usd
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
5301 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4958074 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2173051 usd
CY2022 rvph Income Tax Expense Benefit Including Immaterial Differences
IncomeTaxExpenseBenefitIncludingImmaterialDifferences
20600 usd
CY2021 rvph Income Tax Expense Benefit Including Immaterial Differences
IncomeTaxExpenseBenefitIncludingImmaterialDifferences
8281 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20447371
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
422
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12619407 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11262916 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
117909 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
81911 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
218421 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
197508 usd
CY2022Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
2419 usd
CY2021Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
2557 usd
CY2022Q4 rvph Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
3539335 usd
CY2021Q4 rvph Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5475 usd
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16502966 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11544892 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16502966 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11544892 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4958074 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18477878
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15076630
CY2022Q3 us-gaap Share Price
SharePrice
2.20
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
474173 usd
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
281397 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Price
SharePrice
4.25

Files In Submission

Name View Source Status
0001437749-23-008502-index-headers.html Edgar Link pending
0001437749-23-008502-index.html Edgar Link pending
0001437749-23-008502.txt Edgar Link pending
0001437749-23-008502-xbrl.zip Edgar Link pending
ex_487038.htm Edgar Link pending
ex_487039.htm Edgar Link pending
ex_487040.htm Edgar Link pending
ex_487041.htm Edgar Link pending
ex_487042.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
image02.jpg Edgar Link pending
image03.jpg Edgar Link pending
image04.jpg Edgar Link pending
image05.jpg Edgar Link pending
image06.jpg Edgar Link pending
image07.jpg Edgar Link pending
image08.jpg Edgar Link pending
image09.jpg Edgar Link pending
image10.jpg Edgar Link pending
image11.jpg Edgar Link pending
image12.jpg Edgar Link pending
image13.jpg Edgar Link pending
image14.jpg Edgar Link pending
image15.jpg Edgar Link pending
image17.jpg Edgar Link pending
image18.jpg Edgar Link pending
image19.jpg Edgar Link pending
image20.jpg Edgar Link pending
image21.jpg Edgar Link pending
image22.jpg Edgar Link pending
image23.jpg Edgar Link pending
image24.jpg Edgar Link pending
image25.jpg Edgar Link pending
image26.jpg Edgar Link pending
image27.jpg Edgar Link pending
image28.jpg Edgar Link pending
image29.jpg Edgar Link pending
image30.jpg Edgar Link pending
image31.jpg Edgar Link pending
imagee16.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
r02.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20221231.xsd Edgar Link pending
rvph20221231_10k.htm Edgar Link pending
Show.js Edgar Link pending
rvph-20221231_def.xml Edgar Link unprocessable
rvph-20221231_lab.xml Edgar Link unprocessable
rvph-20221231_pre.xml Edgar Link unprocessable
rvph-20221231_cal.xml Edgar Link unprocessable
rvph20221231_10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable